scispace - formally typeset
P

Peter Youssef

Researcher at Royal Prince Alfred Hospital

Publications -  82
Citations -  3263

Peter Youssef is an academic researcher from Royal Prince Alfred Hospital. The author has contributed to research in topics: Rheumatoid arthritis & Synovial membrane. The author has an hindex of 25, co-authored 75 publications receiving 2874 citations. Previous affiliations of Peter Youssef include University of Sydney & University of New South Wales.

Papers
More filters
Journal Article

Synovial membrane inflammation and cytokine production in patients with early osteoarthritis.

TL;DR: Chronic inflammatory changes with production of proinflammatory cytokines are a feature of synovial membranes from patients with early OA, with the most severe changes seen in patients at the time of joint replacement surgery resembling those seen in rheumatoid arthritis.
Journal ArticleDOI

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, +212 more
- 29 Jul 2017 - 
TL;DR: Tofacitinib monotherapy was not shown to be non-inferior to either combination of adalimumab and methotrexate, and no new or unexpected safety issues were reported for either treatment in this study for up to 1 year.
Journal ArticleDOI

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, +82 more
- 10 Jun 2017 - 
TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.
Journal ArticleDOI

Proinflammatory properties of the human S100 protein S100A12

TL;DR: Human S100A12 induced migration of monocytoid cells, with optimal activity at 10−10 M and potency of >10−9 M C5a, and may contribute to leukocyte migration in chronic inflammatory responses.